StockData
Passage BIO, Inc. logo

Passage BIO, Inc. (PASG) shareholders

PASGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$4.22+0.09 (+2.18%)

Close on Nov 17, 2026Market cap $13.58MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
100.0%
4M of 3M shares
Institutional holders
30
5 new, 9 sold out
Net institutional buying
3M
In Q2 2026
Insider trades, 12 months
1 buys · 2 sales
Net bought $93.04K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Weston Nichols
Joint filing with Lynx1 Capital Management LP (21.00%)
673,75921.00%13D (active)Jun 25, 2026
Lynx1 Capital Management LP
Joint filing with Weston Nichols (19.60%)
623,70419.60%13G (passive) amendmentSep 30, 2025
Orbimed Capital Gp Vii LLC
Joint filing with Orbimed Advisors LLC (7.82%)
243,8787.82%13D (active) amendmentJul 17, 2025
David Paolella
Joint filing with Baselake Partners, LP (7.30%), Baselake Management, LLC (7.30%)
235,0587.30%13G (passive)Jun 18, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of PASGValueChange% of portfolio
Citadel Advisors LLC2,886,12589.69%$4.31MNew0.00%
Lynx1 Capital Management LP673,75920.94%$3.29M+50,0550.38%
Vanguard Capital Management LLC113,9643.54%$556.14K–0.00%
Balyasny Asset Management L.P.107,0253.33%$522.28KNew0.00%
Ikarian Capital, LLC99,5173.09%$485.64K+31,3930.05%
Yiheng Capital Management, L.P.86,0972.68%$420.15K–0.14%
Renaissance Technologies LLC47,8921.49%$233.71K−85,7200.00%
Erste Asset Management GmbH40,6651.26%$197.23K−44,5970.00%
Geode Capital Management, LLC37,0261.15%$180.72K−4,3540.00%
Verdad Advisers, LP30,7280.95%$149.95K+8,6000.14%
Boothbay Fund Management, LLC28,4390.88%$138.78K+9,5680.00%
BlackRock, Inc.27,9100.87%$136.20K−6850.00%
Acadian Asset Management LLC22,4960.70%$109.00K−1,7000.00%
Vanguard Fiduciary Trust Co17,0490.53%$83.20K–0.00%
Deltec Asset Management LLC15,0000.47%$73.20KNew0.01%
UBS Group AG13,5650.42%$66.20K−13,9360.00%
Hrt Financial LP12,7120.40%$62.00KNew0.00%
Fiduciary Trust Co10,7500.33%$52.46K–0.00%
Gts Securities LLC10,0000.31%$48.80KNew0.00%
Morgan Stanley2,3890.07%$11.66K−2610.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026304M100.0%5 / 57 / 93M1M
Q1 2026352M55.3%12 / 64 / 60M0M
Q4 2025302M49.0%6 / 57 / 70M0M
Q3 2025322M51.2%6 / 156 / 150M0M
Q2 2025412M54.5%5 / 910 / 60M0M
Q1 2025422M56.4%2 / 1111 / 60M0M
Q4 2024462M58.5%10 / 1010 / 90M0M
Q3 2024452M60.1%10 / 87 / 90M0M
Q2 2024452M62.6%3 / 811 / 90M0M
Q1 2024512M62.7%7 / 1314 / 81M0M
Q4 2023522M50.9%8 / 1510 / 70M0M
Q3 2023512M50.3%2 / 1413 / 60M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

13 funds held PASG in Q2 2026, 76% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of PASGValue% of fundAs of
Vanguard Total Stock Market Index Fund78,7642.45%$384.37K0.00%Jun 30, 2026
Vanguard Extended Market Index Fund35,2001.09%$171.78K0.00%Jun 30, 2026
Fidelity Extended Market Index Fund18,5350.58%$106.95K0.00%May 31, 2026
Fidelity Total Market Index Fund6,4270.20%$37.08K0.00%May 31, 2026
Fidelity Series Total Market Index Fund4,7830.15%$27.60K0.00%May 31, 2026
LVIP Dimensional U.S. Core Equity 2 Fund2,0220.06%$9.87K0.00%Jun 30, 2026
Fidelity Nasdaq Composite Index Fund1,8970.06%$10.95K0.00%May 31, 2026
Dimensional U.S. Core Equity 2 ETF7920.02%$3.54K0.00%Jul 31, 2026
Diversified Equity Alpha Master Portfolio5040.02%$2.46K0.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
William ChouPRESIDENT AND CEO, Director6,5240.20%Mar 18, 2026
Kathleen BorthwickCFO5,4020.17%Mar 18, 2026
Edgar B. CaleGC & CORPORATE SECRETARY45,9951.43%Mar 18, 2025
Athena CountouriotisDirector18,9000.59%May 21, 2026
Derrell PorterDirector––May 21, 2026
Thomas Richard KassbergDirector––May 21, 2026
Maxine GowenDirector––May 21, 2026
Sandip KapadiaDirector0–May 21, 2026
Dolan SondhiDirector––May 21, 2026
Saqib IslamDirector5,0000.16%May 30, 2025
Weston Nichols10% owner673,75920.94%Jun 29, 2026
Capital Management LP Lynx110% owner591,69618.39%Jun 29, 2026
Capital GP VII LLC OrbiMed10% owner6,885,572213.98%Jun 26, 2025
Advisors Llc Orbimed10% owner6,066,343188.52%Jun 26, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Weston Nichols
10% owner
Jun 25, 2026Buy+50,055$4.12$206.23K673,759
William Chou
PRESIDENT AND CEO, Director
Jan 8, 2026Sale−4,076$18.44$75.16K6,524
William Chou
PRESIDENT AND CEO, Director
Jan 8, 2026Option exercise+10,000––10,600
Kathleen Borthwick
CFO
Jan 8, 2026Sale−2,062$18.44$38.02K5,402
Kathleen Borthwick
CFO
Jan 8, 2026Option exercise+5,000––7,464
Weston Nichols
10% owner
Sep 15, 2025Buy+11,900$6.99$83.18K623,704
Weston Nichols
10% owner
Sep 12, 2025Buy+19,783$6.99$138.28K611,804
Weston Nichols
10% owner
Sep 11, 2025Buy+325$6.96$2.26K592,021
Capital Management LP Lynx1
10% owner
Jul 24, 2025Buy+66,423$5.71$379.28K591,696
Capital Management LP Lynx1
10% owner
Jul 23, 2025Buy+49,302$5.74$282.99K525,273
Capital Management LP Lynx1
10% owner
Jul 22, 2025Buy+13,123$5.44$71.39K475,971
Advisors Llc Orbimed
10% owner
Jun 26, 2025Sale−213,257$0.33$70.37K6,066,343
Advisors Llc Orbimed
10% owner
Jun 25, 2025Sale−138,800$0.33$45.80K6,279,600
Advisors Llc Orbimed
10% owner
Jun 24, 2025Sale−231,600$0.35$81.06K6,418,400
Advisors Llc Orbimed
10% owner
Apr 24, 2025Sale−68,195$0.32$21.82K6,650,000
Advisors Llc Orbimed
10% owner
Apr 23, 2025Sale−89,328$0.34$30.37K6,718,195
Advisors Llc Orbimed
10% owner
Apr 22, 2025Sale−78,049$0.34$26.54K6,807,523
Capital GP VII LLC OrbiMed
10% owner
Apr 17, 2025Sale−77,090$0.33$25.44K6,885,572
Capital GP VII LLC OrbiMed
10% owner
Apr 16, 2025Sale−61,638$0.33$20.34K6,962,662
Capital GP VII LLC OrbiMed
10% owner
Apr 15, 2025Sale−10,326$0.38$3.92K7,024,300
Kathleen Borthwick
CFO
Feb 11, 2025Sale−3,183$0.53$1.69K41,283
Kathleen Borthwick
CFO
Feb 10, 2025Option exercise+8,000––44,466
Advisors Llc Orbimed
10% owner
Jan 14, 2025Sale−79,024$0.60$47.41K7,034,626
Advisors Llc Orbimed
10% owner
Jan 13, 2025Sale−17,986$0.64$11.51K7,113,650
Advisors Llc Orbimed
10% owner
Jan 10, 2025Sale−126,209$0.66$83.30K7,131,636
Capital GP VII LLC OrbiMed
10% owner
Jan 8, 2025Sale−75,007$0.68$51.00K7,257,845
Capital GP VII LLC OrbiMed
10% owner
Jan 7, 2025Sale−52,536$0.71$37.30K7,332,852
Capital GP VII LLC OrbiMed
10% owner
Jan 6, 2025Sale−19,481$0.77$15.00K7,385,388
Capital Management LP Lynx1
10% owner
Dec 27, 2024Buy+373,645$0.65$242.87K9,256,953
Capital GP VII LLC OrbiMed
10% owner
Dec 20, 2024Sale−230,321$0.60$138.19K7,404,869
Advisors Llc Orbimed
10% owner
Dec 11, 2024Sale−80$0.80$647,635,190
Advisors Llc Orbimed
10% owner
Dec 10, 2024Sale−8,015$0.80$6.41K7,635,270
Advisors Llc Orbimed
10% owner
Dec 9, 2024Sale−54,181$0.84$45.51K7,643,285
Capital GP VII LLC OrbiMed
10% owner
Dec 6, 2024Sale−20,903$0.82$17.14K7,697,466
Capital GP VII LLC OrbiMed
10% owner
Dec 4, 2024Sale−76,200$0.79$60.20K7,718,369
Capital Management LP Lynx1
10% owner
Nov 27, 2024Buy+29,300$0.67$19.63K8,883,308
Capital Management LP Lynx1
10% owner
Nov 26, 2024Buy+167,055$0.71$118.61K8,854,008
Capital Management LP Lynx1
10% owner
Nov 25, 2024Buy+259,998$0.56$145.60K8,686,953
Advisors Llc Orbimed
10% owner
Sep 19, 2024Sale−39,300$0.71$27.90K7,794,569
Capital GP VII LLC OrbiMed
10% owner
Sep 18, 2024Sale−25,631$0.73$18.71K7,833,869
Capital GP VII LLC OrbiMed
10% owner
Sep 17, 2024Sale−111,400$0.73$81.32K7,859,500
Capital GP VII LLC OrbiMed
10% owner
Sep 16, 2024Sale−63,100$0.74$46.69K7,970,900
Kathleen Borthwick
SVP, INTERIM CFO
Feb 13, 2024Sale−1,470$0.97$1.43K28,466
Mark S. Forman
CHIEF MEDICAL OFFICER
Feb 13, 2024Sale−1,638$0.97$1.59K48,631
Kathleen Borthwick
SVP, INTERIM CFO
Feb 10, 2024Option exercise+4,000––29,936
Mark S. Forman
CHIEF MEDICAL OFFICER
Feb 10, 2024Option exercise+5,000––50,269
Kathleen Borthwick
SVP, Interim CFO
Jan 2, 2024Sale−10,672$0.91$9.71K25,936
Mark S. Forman
Chief Medical Officer
Jan 2, 2024Sale−15,813$0.91$14.39K45,269
Edgar B. Cale
GC & Corporate Secretary
Jan 2, 2024Sale−15,813$0.91$14.39K45,995
Kathleen Borthwick
SVP, Interim CFO
Dec 31, 2023Option exercise+30,000––36,608
Mark S. Forman
Chief Medical Officer
Dec 31, 2023Option exercise+50,000––61,082
Edgar B. Cale
GC & Corporate Secretary
Dec 31, 2023Option exercise+50,000––61,808
Simona King
Chief Financial Officer
Jul 28, 2023Sale−11,453$0.88$10.08K23,994
Simona King
Chief Financial Officer
Jul 28, 2023Option exercise+31,250––35,447
Advisors Llc Orbimed
10% owner
Jun 28, 2023Buy+575,195$0.84$483.16K8,034,000
Advisors Llc Orbimed
10% owner
Jun 27, 2023Buy+617,382$0.84$518.60K7,458,805
Alexandros Fotopoulos
Chief Technical Officer
Jun 16, 2023Sale−4,052$0.93$3.77K28,693
Alexandros Fotopoulos
Chief Technical Officer
Jun 15, 2023Option exercise+12,500––32,745
Simona King
Chief Financial Officer
Apr 18, 2023Sale−2,053$1.05$2.16K2,053
Simona King
Chief Financial Officer
Apr 18, 2023Option exercise+6,250––6,250

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
2.13%
0M shares short
Days to cover
4.0
At 0M shares a day
Change since last report
-28.1%
From 0M shares
Short volume, 20 days
61.4%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Passage BIO's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
William Chou
Officer
Jan 9, 20264,076$75.12KJan 9, 2026Restricted Stock
OrbiMed Private Investments VII, LP
Stockholder
Jul 21, 2025132,645$737.51KJul 21, 2025IPO
OrbiMed Private Investments VII, LP
Stockholder
Jul 15, 202553,293$361.86KJul 15, 2025IPO
OrbiMed Private Investments VII, LP
Stockholder
Jul 7, 2025259,000$112.15KJul 7, 2025IPO
OrbiMed Private Investments VII, LP
Stockholder
Jun 24, 20251,076,120$378.36KJun 24, 2025IPO
OrbiMed Private Investments VII, LP
Stockholder
Apr 15, 2025787,179$301.49KApr 15, 2025IPO
OrbiMed Private Investments VII, LP
Stockholder
Jan 6, 20251,140,740$945.67KJan 6, 2025IPO
OrbiMed Private Investments VII, LP
Stockholder
Dec 4, 20242,985,518$2.66MDec 4, 2024IPO
Worldwide Healthcare Trust PLC
Stockholder
Dec 4, 20242,028,307$1.81MDec 4, 2024IPO
OrbiMed Private Investments VII, LP
Owner
Sep 16, 2024927,572$748.55KSep 16, 2024IPO
Worldwide Healthcare Trust PLC
Owner
Sep 16, 2024241,328$194.75KSep 16, 2024IPO

See a number that looks wrong?